Drug firms have new medicines and patients are desperate for them. But the arguments over cost are growing
LOUIS MACHOGU, the owner of a pharmacy near Nairobi, has noticed a change. In the past decade Kenya, like much of Africa, has seen a surge in foreign aid to fight infectious diseases. Thanks to antiretroviral treatments, HIV is no longer a death sentence. But the decline of one scourge means that people are living long enough to fall sick in other ways. “The same way we had HIV killing people,” Dr Machogu says, “we now have hypertension and cancer.”
Treatment often depends on the whim of pharmaceutical firms’ philanthropic programmes. Cancer drugs are particularly lacking. The Kenya Medical Supplies Agency buys medicines for public hospitals, but not those for cancer.
In Tampa, Florida, Marilyn Weisman also depends on charity for treatment. The 72-year-old thought she had a bad rash. She turned out to have cutaneous T-cell lymphoma, a rare cancer. Though she is insured, she could not afford her share of the payment for the drug her doctors recommended. So a pharmacist at her hospital, Moffitt Cancer Centre, helped her to apply for charitable aid. Mrs Weisman’s situation is surprisingly common for American cancer sufferers. Many insured patients in one of the world’s richest countries cannot afford their medicines.
A new drug war is looming. The market is growing: patients in rich countries are ageing and those in developing ones are getting richer and suffering from chronic diseases. But as demand for drugs rises, so does concern at their price. A record $1 trillion will be spent globally on medicines in 2014, predicts IMS Health, a research firm. “The costs of many new medical products are becoming unsustainable for even the wealthiest countries in the world,” said Margaret Chan, the head of the World Health Organisation (WHO), in August.
On every front
Skirmishes are breaking out from Brunei to New England. Negotiators for the Trans-Pacific Partnership (TPP), a giant trade deal that would cover 12 countries, including America, are battling over access to medicines. Health activists are trying to block a costly Hepatitis C drug from being patented in India. Brazil and South Africa are mulling over patent reforms that could make drugs cheaper.
Eli Lilly, an American pharmaceutical firm, is suing Canada for letting competitors sell copies of two medicines there, which it says violates the North American Free Trade Agreement. In October Maine became the first American state to allow drugs purchases from cheaper foreign online pharmacies. The drugmakers’ lobby has sued, charging that the policy is an attempt to circumvent federal law.
Meanwhile firms are crunching reams of data to prove their wares’ worth. But even as they try to justify high costs, they are testing new pricing models. “The starting point always is, what is the right price for a medicine?” says Severin Schwan, the chief executive of Roche, a Swiss pharmaceutical giant. “And there is no objective answer…At the end you are discussing, what is the price of life?”
Drug development is expensive, slow and chancy, so pharmaceutical firms charge a lot. But if drugs are too pricey, support for patents will collapse. Ian Read, the boss of Pfizer, an American giant, recently laid out the threat: “Unless we’re respected by society, unless we’re seen as good stewards of our resources, then we run the risk of both losing patents and losing the ability to price our medications.”
The Latest on: Cost of drugs
via Google News
The Latest on: Cost of drugs
- Froma Harrop: We can stop being the world's suckers on drug priceson October 13, 2021 at 8:53 am
We Can Stop Being the World's Suckers on Drug Prices. There's a drug war on TV. It has nothing to do with cocaine or heroin but does involve an addiction -- the pharmaceutical ind ...
- Majority of Americans back Medicare drug price negotiationon October 13, 2021 at 6:54 am
Despite polling favorably, lawmakers have yet to reach a consensus on whether to include such a provision in the reconciliation bill.
- BioLineRx: Pharmacoeconomic Study Shows Cost Benefits Of Using Motixafortide With G-CSFon October 13, 2021 at 6:04 am
(BLRX) reported positive results from a pharmacoeconomic study evaluating the cost-effectiveness of using investigational drug Motixafortide as a primary stem cell mobilization agent on top of ...
- Froma Harrop: Let's finally let Medicare negotiate prescription drug priceson October 13, 2021 at 1:00 am
There’s a drug war on TV. It has nothing to do with cocaine or heroin but does involve an addiction — the pharmaceutical industry’s compulsion to charge Americans an average 3.4 times more for ...
- Opinion | Drug Companies Say We Can Have Innovation or Lower Prices. That’s a False Choice.on October 12, 2021 at 8:30 pm
The debate in Congress over negotiating drug prices is based on a phony premise that higher prices are needed to fund pharmaceutical R&D.
- Cost of Merck COVID-19 Pill: How Treatment Compares to Vaccines, Monoclonal Antibodieson October 12, 2021 at 10:56 am
Merck's COVID-19 oral antiviral pill would be a cheaper solution to outpatient therapeutics than monoclonal antibody treatments, but it's still 17 times more expensive than getting vaccinated against ...
- Majority wants Medicare to be able to negotiate drug priceson October 12, 2021 at 10:03 am
Large majorities regardless of party identification and age found the following argument convincing: “Those in favor say negotiation is needed because Americans pay higher prices than people in other ...
- Editorial: The government could, and should, save billions on Medicare drug priceson October 11, 2021 at 1:55 pm
Allowing the government to negotiate Medicare drug prices could save hundreds of billions of dollars a year. So why isn't that happening?
- Price Controls Will Not Lower Drug Priceson October 10, 2021 at 9:01 pm
There are 58 million Americans who cannot afford the drugs they need, and 34 million adults know someone who died because they could not afford medications. Earlier this month, the ...
- Ban on negotiating drug prices under pressureon October 7, 2021 at 2:00 am
For Medicare "to negotiate those prices down would be thousands of dollars back in my pocket every year," she said. Negotiating Medicare drug prices is the linchpin of President Joe Biden's ambitious ...
via Bing News